Imbio PHA (4.0.0) vs uOmnispace.MI
AI Verdict
Choose Imbio PHA (4.0.0) if…
Choose Imbio PHA (4.0.0) if your primary need is rapid, automated, and AI-powered analysis of cardiac structures specifically from CT pulmonary angiogram (CTPA) scans. This tool is ideal for quickly assessing right ventricular dilation and aiding in the diagnosis and risk stratification of pulmonary embolism and hypertension, providing automated measurements and summary reports.
View Imbio PHA (4.0.0) →Choose uOmnispace.MI if…
Choose uOmnispace.MI if you require a versatile, multi-modality imaging platform for comprehensive 2D and 3D viewing, advanced AI-enhanced segmentation, and quantitative analysis across various clinical specialties. This solution is best suited for complex cases in oncology, neurology, and cardiology that demand detailed image registration, lesion segmentation, and collaborative multi-user access for PET, CT, MR, and SPECT images.
View uOmnispace.MI →Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Quick Comparison
| Feature | Imbio PHA (4.0.0) | uOmnispace.MI |
|---|---|---|
| Deployment | Cloud (AWS) or On-premise (VMware) or via partners (Nuance, Aidoc, Siemens Syngo.via, TeraRecon, FerrumHealth, Flywheel). | Unknown |
| FDA Status | Yes AI-estimated | Unknown |
Head-to-Head
AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.
Usability
Imbio PHA (4.0.0)Imbio PHA emphasizes 'Rapid, fully-automated assessment (typically in minutes)' and seamless integration with native DICOM tools and workflows, delivering annotated images and summary reports directly into the PACS without additional steps for the physician. This focus on minimal disruption to existing clinical practices and automated results suggests a highly streamlined and efficient user experience for its specific task.
Clinical Value
Imbio PHA (4.0.0)Imbio PHA is an FDA-cleared AI-powered software specifically designed to automatically measure cardiac structures from CTPA scans to assess potential right ventricular dilation, aiding in the diagnosis and risk stratification of pulmonary embolism and hypertension. This provides a clear, validated, and direct clinical utility for critical conditions. While uOmnispace.MI offers broad AI-enhanced analysis, its clinical value is described more generally as supporting workflows across multiple specialties rather than providing a specific diagnostic aid for a particular condition with FDA clearance for that specific aid.
Pricing & Value
TieBoth tools explicitly state 'contact for pricing' or 'contact vendor,' indicating a lack of transparent pricing information. Without specific cost details or publicly available pricing models, it is impossible to conduct a head-to-head comparison of their financial value or cost-effectiveness.
Enterprise Readiness
Imbio PHA (4.0.0)Both tools demonstrate strong enterprise readiness with flexible deployment options (cloud, on-premise, hybrid/SaaS), HIPAA compliance, and FDA clearance. However, Imbio PHA's explicit mention of 'third-party certified by compliancy group' for HIPAA compliance provides an additional layer of assurance and trust for enterprise-level data security and regulatory adherence.
Innovation
uOmnispace.MIWhile Imbio PHA offers innovative, automated AI for specific cardiac measurements, uOmnispace.MI demonstrates broader innovation by applying AI-enhanced segmentation across multiple imaging modalities (PET, CT, MR, SPECT) and offering advanced features like AI-based rib extraction, dynamic PET data analysis, and remote multi-user access. This breadth of AI application and advanced analytical capabilities across diverse specialties suggests a wider scope of innovation.
Support & Docs
TieNeither the provided structured facts nor general web searches offer specific details regarding the depth, availability, or quality of support and documentation for either tool beyond general customer support availability. Therefore, it is not possible to distinguish between them on this dimension.
Feature-by-Feature
Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.
| Feature | Imbio PHA (4.0.0) | uOmnispace.MI |
|---|---|---|
| Name | Imbio PHA (4.0.0) | uOmnispace.MI |
| Company | Imbio | Shanghai United Imaging Healthcare Co. |
| Description | FDA-cleared AI-powered medical image processing software that automatically measures cardiac structures from CT pulmonary angiogram (CTPA) scans to assess potential right ventricular dilation and aid in the diagnosis and risk stratification of pulmonary embolism and hypertension. | Advanced medical imaging software that provides comprehensive 2D and 3D viewing, AI-enhanced segmentation, and analysis tools for PET, CT, MR, and SPECT images, supporting clinical workflows in oncology, neurology, and cardiology. |
| Categories | Cardiology AI, Radiology & Imaging AI | Cardiology AI, Neurology AI, Oncology AI |
| Specialties | Cardiology, Pulmonology, Radiology | Nuclear Medicine, Oncology, Radiology |
| Key Features | Automated measurement of right and left ventricle diameters, automated measurement of main pulmonary artery and aorta diameters, calculates RV/LV and PA/Ao ratios, utilizes artificial intelligence algorithms for anatomical identification and measurement, generates annotated DICOM images, provides summary reports in PDF format, integrates with native DICOM tools and workflows, rapid, fully-automated assessment (typically in minutes). | 2D and 3D medical image viewing, annotation and measurement tools, manual and automatic segmentation (including AI-based rib extraction), support for DICOM images across CT, MRI, PET, SPECT modalities, remote multi-user access on a network, image registration and lesion segmentation, quantitative analysis and fusion imaging, dynamic PET data analysis. |
Videos
Demos, reviews, and walkthroughs featuring Imbio PHA (4.0.0) and uOmnispace.MI.